Sporadic ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells

Anti-cancer drugs commonly target signal transduction proteins activated by mutation. In patients with BRAFV600E melanoma, small molecule RAF and MEK kinase inhibitors cause dramatic but often transient tumor regression. Emerging evidence suggests that cancer cells adapting by non-genetic mechanisms constitute a reservoir for the development of drug-resistant tumors. Here, we show that few hours after exposure to RAF/MEK inhibitors, BRAFV600E melanomas undergo adaptive changes involving disruption of negative feedback and sporadic pulsatile reactivation of the MAPK pathway, so that MAPK activity is transiently high enough in some cells to drive proliferation. Quantitative proteomics and computational modeling show that pulsatile MAPK reactivation is possible due to the co-existence in cells of two MAPK cascades: one driven by BRAFV600E that is drug-sensitive and a second driven by receptors that is drug-resistant. Paradoxically, this may account both for the frequent emergence of drug resistance and for the tolerability of RAF/MEK therapy in patients.

[1]  Peter K. Sorger,et al.  Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway , 2016, Science Signaling.

[2]  E. Winer,et al.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. , 2016, Cancer cell.

[3]  D. Morrison,et al.  Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. , 2013, Molecular cell.

[4]  Christof Fellmann,et al.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.

[5]  T. Burke,et al.  RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1 , 2018, Oncogene.

[6]  B. Kholodenko,et al.  The dynamic control of signal transduction networks in cancer cells , 2015, Nature Reviews Cancer.

[7]  G. Guy,et al.  A Src Homology 3-binding Sequence on the C Terminus of Sprouty2 Is Necessary for Inhibition of the Ras/ERK Pathway Downstream of Fibroblast Growth Factor Receptor Stimulation* , 2006, Journal of Biological Chemistry.

[8]  A. Dar,et al.  Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling , 2016, Nature.

[9]  A. Tolcher,et al.  Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors , 2018, Molecular Cancer Therapeutics.

[10]  Mohammad Fallahi-Sichani,et al.  Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis , 2015 .

[11]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[12]  Fabian J. Theis,et al.  Scalable Parameter Estimation for Genome-Scale Biochemical Reaction Networks , 2016, bioRxiv.

[13]  A. Viale,et al.  Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And , 2022 .

[14]  N. Haass,et al.  Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance , 2018, Front. Oncol..

[15]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[16]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[17]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[18]  Oleksii S. Rukhlenko,et al.  MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. , 2016, Current opinion in structural biology.

[19]  Oleksii S. Rukhlenko,et al.  Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. , 2018, Cell systems.

[20]  Philippe P Roux,et al.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.

[21]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[22]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[23]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[24]  R. Bernards,et al.  Drug resistance to targeted therapies: Déjà vu all over again , 2014, Molecular oncology.

[25]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[26]  James R. Faeder,et al.  Energy-based modeling in BioNetGen , 2016, 2016 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[27]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[28]  Chris J. Myers,et al.  The Systems Biology Markup Language (SBML): Language Specification for Level 3 Version 2 Core , 2018, J. Integr. Bioinform..

[29]  M. Eccles,et al.  The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma , 2017, Molecular Cancer Therapeutics.

[30]  Corey E. Hayford,et al.  A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma. , 2018, Biophysical journal.

[31]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[32]  Anne E Carpenter,et al.  CellProfiler: free, versatile software for automated biological image analysis. , 2007, BioTechniques.

[33]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[34]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[35]  S. Spencer,et al.  Irreversible APCCdh1 Inactivation Underlies the Point of No Return for Cell-Cycle Entry , 2016, Cell.

[36]  Aaron S. Meyer,et al.  Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition , 2018, Cellular and Molecular Bioengineering.

[37]  J. Engelman,et al.  Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.

[38]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[39]  B. Kholodenko.  Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. , 2015, Cell reports.

[40]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[41]  Sandro Santagata,et al.  Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.

[42]  Tao Liu,et al.  Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway. , 2018, Analytical chemistry.

[43]  Honda Naoki,et al.  Intercellular propagation of extracellular signal-regulated kinase activation revealed by in vivo imaging of mouse skin , 2015, eLife.

[44]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[45]  Carlos F. Lopez,et al.  Programming biological models in Python using PySB , 2013, Molecular systems biology.

[46]  Zhongzhou Chen,et al.  Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis , 2018, Science Signaling.

[47]  Eytan Domany,et al.  Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. , 2011, Molecular cell.

[48]  Saroja Ramanujan,et al.  Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model , 2017, npj Systems Biology and Applications.

[49]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[50]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[51]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[52]  Bernd Bodenmiller,et al.  miCAT: A toolbox for analysis of cell phenotypes and interactions in multiplex image cytometry data , 2017, Nature Methods.

[53]  Jacob J. Hughey,et al.  High-Sensitivity Measurements of Multiple Kinase Activities in Live Single Cells , 2014, Cell.

[54]  Thomas L. Fillmore,et al.  Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins , 2017, Oncotarget.

[55]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[56]  Kazuhiro Aoki,et al.  Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. , 2013, Molecular cell.

[57]  Chris J. Myers,et al.  The Systems Biology Markup Language (SBML): Language Specification for Level 3 Version 2 Core Release 2 , 2018, J. Integr. Bioinform..

[58]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[59]  H. Wiley,et al.  An integrated model of epidermal growth factor receptor trafficking and signal transduction. , 2003, Biophysical journal.

[60]  N. Rosen,et al.  Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. , 2014, Cancer cell.

[61]  E. Pazarentzos,et al.  Adaptive stress signaling in targeted therapy resistance in cancer , 2015, Oncogene.

[62]  Levi A Garraway,et al.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state , 2017, Molecular systems biology.

[63]  Ullrich Köthe,et al.  Ilastik: Interactive learning and segmentation toolkit , 2011, 2011 IEEE International Symposium on Biomedical Imaging: From Nano to Macro.

[64]  Sarat Chandarlapaty,et al.  Negative feedback and adaptive resistance to the targeted therapy of cancer. , 2012, Cancer discovery.

[65]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[66]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[67]  John G. Albeck,et al.  Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. , 2013, Molecular cell.

[68]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[69]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.